Results 181 to 190 of about 284,081 (298)
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami +10 more
wiley +1 more source
Cervical facet joint interventions for neck pain: an anatomically and clinically focused review. [PDF]
Won HS, Kim YD.
europepmc +1 more source
Effects of Head and Neck Massage on Anxiety, Pain, and Discomfort in Hysterectomy Patients
Eun Young Kim, Euy-Soon Choi
openalex +1 more source
Objective To develop evidence‐based criteria to classify SURF patients. Methods 112 SURF patients followed in a single tertiary referral center were analyzed. Patients with genetically confirmed hereditary recurrent fever (HRF) or with periodic fever, aphthosis, pharyngitis and adenitis (PFAPA) syndrome already analyzed for the Eurofever classification
Riccardo Papa +54 more
wiley +1 more source
A population-based survey of beliefs about neck pain and its associated disorders: a cross-sectional study. [PDF]
Forte M +11 more
europepmc +1 more source
Objectives Femoroacetabular impingement (FAI) and synovitis have been recognized as essential factors for developing osteoarthritis (OA) in the hip joints. However, little is known about altered synovial cellular compositions, their associated transcriptomic profiles, and cell‐cell interactions in FAI and hip OA.
Gulzada Kulzhanova +9 more
wiley +1 more source
Prevalence and Underreporting of Crowned Dens Syndrome-Associated Calcifications on Cervical Spine CT in Patients with Neck Pain. [PDF]
Dor S, Eshed I, Lidar M.
europepmc +1 more source
Treatment of Chronic Neck Pain with Transcranial Direct Current Stimulation: A Single-Blinded Randomized Clinical Trial [PDF]
Manuel Rodríguez-Huguet +6 more
openalex +1 more source
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi +12 more
wiley +1 more source

